Abstract
Objective-To determine the prevalence, incidence, and persistence of positivity for antibodies to hepatitis C virus (anti-HCV) and the potential for sexual transmission of the virus.
Design-A cohort analysis covering 1981-9 comparing estimated cumulative incidences of and seroconversion rates for anti-HCV with those of hepatitis B core antibody (anti-HBc) and antibodies to the human immunodeficiency virus (anti-HIV).
Setting-Copenhagen and Aarhus, Denmark. Subjects-259 Male members of a Danish homosexual organisation.
Main outcome measures-Correlations of prevalence and incidence with a wide range of sexual lifestyle variables.
Results-Only four (1-6%) subjects were positive for anti-HCV in 1981. The estimated cumulative incidence of positivity for anti-HCV was 41% in 1984 (seroconversion rate during 1981-4 (2-5%)) and remained at 4-1% in 1989 (seroconversion rate nil during 1984-9). In contrast, positivity for anti-HBC rose from 44 0% in 1981 to 52-7% in 1984 (seroconversion rate 15-5%) and 58-8% in 1989 (serconversion rate 12-9%), and that for anti-HIV rose from 8-8% to 24-0% (seroconversion rate 16-7%) and 30-1% (seroconversion rate 8.0%) respectively. Three anti-HCV positive patients seroreverted three to five years later. None of the anti-HCV positive subjects had had a transfusion and only one gave a past history of intravenous drug use. Variables in sexual lifestyle correlated with the presence of antiHBc but not with that of anti-HCV.
Introduction
Although the classification and early descriptions of clinical non-A non-B hepatitis were derived primarily from cases associated with transfusion, this mode of transmission has recently been estimated to account for only 5 A log linear model was used to compute the nonparametric maximum likelihood estimate of the survival curves (1-estimated cumulative antibody incidence) from interval censored data, as detailed elsewhere.'2 We also calculated the seroconversion rates between years of testing using the same methodology. Associations between serological markers and variables in lifestyle were analysed by Spearman rank order correlations and linear regressions.
Serum samples were kept frozen at -70°C until assay and had not previously been thawed. All serum samples were tested for antibodies to hepatitis C virus (anti-HCV) by an enzyme linked immunosorbent assay (ELISA; Ortho Diagnostic Systems). Samples that were non-reactive to hepatitis C virus in the initial run were considered to be anti-HCV negative. Samples that were reactive to hepatitis C virus were retested and considered to be positive if reactive in both tests.
Exposure to hepatitis B was determined by an assay for antibodies to hepatitis B core antigen (anti-HBc; CORZYME, Abbott Laboratories). This marker does not recognise patients immunised by vaccination. (table II) . This analysis included anti-HCV positive subjects who later seroreverted.
Two of the three men who seroconverted to hepatitis C virus between 1981 and 1984 also seroconverted to HIV during that period. By 1989 these two subjects were profoundly immunosuppressed (CD4 to CD8 ratios 0 20 and 0 04) and one had lost antibody to hepatitis C virus. The third seroconverter was anti-HIV negative throughout, yet had also lost reactivity to hepatitis C virus by 1989. None of the subjects on whom information was available had ever received a transfusion, and only one had ever used drugs intravenously (table I) . Neither age, duration of homosexual activity, type of sexual activity, treatment for venereal disease, nor HIV state was significantly correlated with being anti-HCV positive (figure). The few anti-HCV positive subjects, however, tended to have more partners than seronegative subjects. detail in order to contrast the findings with reactivity to hepatitis C virus. Had hepatitis C been readily transmitted sexually we should expect to have seen a characteristic epidemiological profile. We found no direct evidence of sexual transmission of hepatitis C. Nevertheless, although few of our cohort of homosexual men were positive for anti-HCV, the proportion was considerably higher than that among male blood donors (O 3%) of the same age in Denmark (Wantzin et al, unpublished data). Yet none of our anti-HCV positive subjects had ever received a transfusion and only one gave a history of intravenous drug use. The absence of parenteral exposure favours the possibility of sexual transmission, although at a much lower rate than in the case of hepatitis B virus or HIV. Rates of seroconversion detected to hepatitis C virus were six to 13 times lower than those recorded to hepatitis B virus and HIV.
HEPATITIS B VIRUS AND HIV
One caveat arose from the longitudinal data: the hepatitis C marker was not consistently present among all initially reactive or seroconverting subjects. Loss of anti-HCV has also been described in three patients with resolving non-A non-B hepatitis in a prospective study of transfusion recipients.'3 We have reported declines in reactivity to hepatitis B virus, sometimes to undetectable levels, with progressive immunodeficiency'4 and also observed the phenomenon with anti-HBc in this study. Not all subjects who lost reactivity to hepatitis C virus in this study were infected with HIV and had abnormal immunity, however, which argues for a different explanation for the phenomenon of seroreversion to hepatitis C virus.
Our observation that seroreversion to hepatitis C virus may be fairly common suggests that the cumulative incidence of seropositivity for the period 1981-9 may have been slightly higher than the 4 1% recorded in this study. Alter et al, however, found the mean duration of anti-HCV positivity among subjects who later seroreverted to be 4-1 years (range 7 months to 11 years). " Hence the number of anti-HCV positive subjects missed in our series was probably small.
The persistence of reactivity in some subjects may indicate that some of these men were chronic carriers of hepatitis C. Although a test for hepatitis C virus in the blood is not available, we note that the highest figures for the prevalence of circulating anti-HCV are reportedly found among patients with chronic non-A non-B hepatitis and that among these patients seroreversion is unlikely to occur.'3 The high prevalence of anti-HCV in patients with haemophilia and intravenous drug users4 6-8 may be explained by these people being chronic carriers or recurrently exposed to hepatitis C virus.
We conclude that hepatitis C virus is not readily spread by homosexual activity, although sexual transmission may occur occasionally. Anti-HCV positive subjects may lose their antibodies and it remains to be seen whether those people are less infectious than persistently seropositive subjects. 
